title: Blood absolute T cell counts may predict 2-month treatment response in patients with pulmonary tuberculosis.
abstract: OBJECTIVE
  Little is known about the usefulness of lymphocyte subsets as early predictors of anti-tuberculosis (TB) treatment response in immuno-competent patients.
  
  
  METHODS
  Among a total of 64 patients with culture positive pulmonary TB, 29 remained sputum smear/culture positive or had delayed resolution on CXR (slow responders (SR)), and 35 had sputum culture conversion to negative and rapid resolution on CXR (fast responders (FR)) after two months of anti-tuberculosis treatment. Clinical parameters and lymphocyte subsets were investigated.
  
  
  RESULTS
  A larger proportion of patients in the SR group had cavities on CXR, bilateral lung involvement, positive acid-fast bacilli stains, and complaint of cough at diagnosis than those in the FR group. Absolute counts of CD3+ T cells (p = 0.016) and CD8+ T cells (p=0.012) at diagnosis were both significantly higher in the SR group. This trend was present throughout the 6-month treatment course. Absolute T cell counts (odds ratio (OR) 1.002, 95% confidence interval (CI) 1.0-1.004), positive sputum acid fast bacilli stain (OR 6.69, 95% CI 1.37-32.77) and bilateral lung involvement on CXR (OR 13.114, 95% CI 1.87-92.14) at diagnosis were independent predictors for a slow response. Combining these three predictors, a prediction score (PS) could be calculated to display an optimal discrimination for slow response (area under the curve (AUC)=0.855, p < 0.001), whereas absolute T cell counts yielded the highest discriminative value on an individual level (AUC= 0.676, p=0.015).
  
  
  CONCLUSIONS
  A higher T cell count at diagnosis in patients with TB may predict a slow response to two months of treatment. The calculation of a PS further increased predictive accuracy and performance.
authors.affiliation: Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Chang Gung Memorial Hospital-Kaohsiung Medical Center, Chang Gung University College of Medicine, Kaohsiung, Taiwan.
authors.forename: Yung-Che
authors.initials: YC
authors.lastname: Chen
authors.forename: Huang-Chih
authors.initials: HC
authors.lastname: Chang
authors.forename: Chung-Jen
authors.initials: CJ
authors.lastname: Chen
authors.forename: Shih-Feng
authors.initials: SF
authors.lastname: Liu
authors.forename: Chien-Hung
authors.initials: CH
authors.lastname: Chin
authors.forename: Chao-Chien
authors.initials: CC
authors.lastname: Wu
authors.forename: Tung-Ying
authors.initials: TY
authors.lastname: Chao
authors.forename: Chien-Hao
authors.initials: CH
authors.lastname: Lie
authors.forename: Chin-Chou
authors.initials: CC
authors.lastname: Wang
authors.forename: Meng-Chih
authors.initials: MC
authors.lastname: Lin
mesh_terms: D000995:Antitubercular Agents / Q000627:therapeutic use*; D001772:Blood Cell Count; D017252:CD3 Complex / Q000378:metabolism; D005260:Female; D006801:Humans; D018655:Lymphocyte Count; D008297:Male; D008875:Middle Aged; D010641:Phenotype; D011446:Prospective Studies; D013183:Sputum / Q000737:chemistry; D015996:Survival Rate; D013601:T-Lymphocytes / Q000378:metabolism*; D016896:Treatment Outcome; D014397:Tuberculosis, Pulmonary / Q000097:blood / Q000175:diagnosis* / Q000188:drug therapy*
chemical_list: D000995:Antitubercular Agents; D017252:CD3 Complex